News | Heart Failure | May 16, 2016

New Radar Technology May Reduce Heart Failure Re-Hospitalization

Minneapolis Heart Institute Foundation selected to test product that detects worsening heart failure before patient notices symptoms

May 16, 2016 – To work towards a better method of diagnosis and treatment of congestive heart failure (CHF), Peter Eckman, M.D., with the Minneapolis Heart Institute Foundation (MHIF) is an investigator leading the SMILE (Sensible Medical Innovations Lung fLuid status monitor allows rEducing readmission rate of heart failure patients) study at Abbott Northwestern Hospital, Minneapolis. This study will involve the use of the SensiVest, a product developed by Sensible Medical Innovations, headquartered in Israel. SensiVest is comprised of a wearable vest, with two embedded sensors, and a bedside console.

Patients with CHF are at risk of re-hospitalization when fluid builds up in their lungs. By the time symptoms such as shortness of breath or increased fatigue are present, the fluid build-up often requires medical intervention. This is stressful for the patient, and it’s also costly; the annual cost for CHF treatment in the United States is $30 billion, with half of that going toward hospitalization.

In this study, SensiVest is worn by CHF patients once a day, for a 90-second measurement, to measure the amount of fluid in their lungs. The results are provided to their physician via a secured Web portal. There is no surgery involved, nor does the patient need to visit a clinic or hospital to obtain readings. The physician can review the results and take proactive measures, such as changing medications or dosages, before the patient develops symptoms.

Eckman noted, β€œUsing non-invasive technology to detect fluid buildup in heart failure patients improves our ability to direct treatment before a problem arises, and may reduce risk of re-hospitalization, which is good for the patient and can reduce healthcare costs. We are excited to be part of this type of innovative work.”

A study initially conducted in Israel reported that hospital readmission rates were reduced by 87 percent for patients who were part of the study. Sensible Medical Innovations selected the MHIF as one of 15 sites currently testing the SensiVest in the United States, with plans to expand the study to more hospitals in the future.

Watch a VIDEO showing how the vest works and to hear more about the system.

For more information: www.sensible-medical.com


Related Content

News | Heart Failure

April 16, 2024 β€” Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally ...

Home April 16, 2024
Home
News | Heart Failure

April 12, 2024 β€” University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 β€” People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 β€” V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 β€” A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 β€” BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 β€” BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 β€” BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
News | Heart Failure

March 8, 2024 β€” The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State ...

Home March 08, 2024
Home
News | Heart Failure

March 5, 2024 β€” FIRE1 announced that it has completed patient enrollment in the U.S. Early Feasibility Study (FUTURE-HF2 ...

Home March 05, 2024
Home
Subscribe Now